These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 19523046

  • 1. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C, Smith P, Morrison R, Riek M, Patel A, Schmitt C, Morcos PN, Zhang X.
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
    Chittick GE, Zong J, Blum MR, Sorbel JJ, Begley JA, Adda N, Kearney BP.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1304-10. PubMed ID: 16569845
    [Abstract] [Full Text] [Related]

  • 3. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M, Müller M, Donath F, Mrozikiewicz M, Möcklinghoff C.
    Eur J Med Res; 1999 Mar 26; 4(3):101-4. PubMed ID: 10085276
    [Abstract] [Full Text] [Related]

  • 4. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.
    Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Buggé CJ, Ljungqvist A, Espinosa O, Hewitt RG.
    J Clin Pharmacol; 2004 Mar 26; 44(3):293-304. PubMed ID: 14973306
    [Abstract] [Full Text] [Related]

  • 5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 26; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 6. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P.
    Antivir Ther; 2004 Apr 26; 9(2):247-56. PubMed ID: 15134187
    [Abstract] [Full Text] [Related]

  • 7. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 26; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N, Kageyama M, Kishida T, Kimura K, Yoshikawa Y, Kuwahara T, Toh J, Shirasaka T, Takada K.
    Biopharm Drug Dispos; 2003 Nov 26; 24(8):335-44. PubMed ID: 14595702
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P, Zilly M, Weissbrich B, Schlör C, Väth T, Richter E, Klinker H.
    Eur J Med Res; 2000 Feb 28; 5(2):59-62. PubMed ID: 10720564
    [Abstract] [Full Text] [Related]

  • 10. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B, Riek M, Holmes B, Grange S.
    Antivir Ther; 2005 Feb 28; 10(7):803-10. PubMed ID: 16312177
    [Abstract] [Full Text] [Related]

  • 11. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
    Buss N, Snell P, Bock J, Hsu A, Jorga K.
    Br J Clin Pharmacol; 2001 Sep 28; 52(3):255-64. PubMed ID: 11560557
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.
    Antimicrob Agents Chemother; 2006 Mar 28; 50(3):928-34. PubMed ID: 16495253
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
    King JR, Kakuda TN, Paul S, Tse MM, Acosta EP, Becker SL.
    J Clin Pharmacol; 2007 Feb 28; 47(2):201-8. PubMed ID: 17244771
    [Abstract] [Full Text] [Related]

  • 14. [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].
    Tsuchiya K, Hirabayashi Y, Imai K, Kikuchi Y, Tachikawa N, Genka I, Teruya K, Yasuoka A, Oka S, Kimura S.
    Kansenshogaku Zasshi; 2003 Jun 28; 77(6):436-42. PubMed ID: 12872693
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Apr 28; 59(4):690-7. PubMed ID: 17307771
    [Abstract] [Full Text] [Related]

  • 16. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
    Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH, Hoetelmans RM.
    J Acquir Immune Defic Syndr; 2001 Aug 01; 27(4):344-9. PubMed ID: 11468422
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
    Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.
    J Acquir Immune Defic Syndr; 2003 Apr 01; 32(4):375-9. PubMed ID: 12640194
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.
    Antimicrob Agents Chemother; 2007 Apr 01; 51(4):1431-9. PubMed ID: 17296738
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD, MaxCmin1 Trial Group.
    J Infect Dis; 2003 Sep 01; 188(5):635-42. PubMed ID: 12934178
    [Abstract] [Full Text] [Related]

  • 20. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE, COL104422 Study Team.
    HIV Med; 2010 Mar 01; 11(3):193-9. PubMed ID: 19863619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.